Claims for Patent: 11,648,232
✉ Email this page to a colleague
Summary for Patent: 11,648,232
| Title: | Methods and compositions for treating excessive sleepiness |
| Abstract: | The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests. |
| Inventor(s): | Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi |
| Assignee: | Axsome Malta Ltd |
| Application Number: | US17/212,079 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,648,232 |
| Patent Claims: |
1. A method of improving excessive sleepiness in a human patient in need thereof, said method comprising administering [R]-2-amino-3-phenylpropylcarbamate (APC) or a pharmaceutically acceptable salt thereof to the human patient in accordance with a dosing regimen, said dosing regimen comprising a once-daily dose of 75 mg for at least 3 days followed by a once-daily dose of 150 mg, wherein the once-daily dose of 150 mg is the maximum dose in the dosing regimen, thereby improving excessive sleepiness in the human patient. 2. The method of claim 1, wherein the dosing regimen comprises a starting dose of 75 mg once daily for 3 days followed by a dose of 150 mg once daily. 3. The method of claim 1, wherein the dosing regimen comprises a starting dose of 37.5 mg once daily. 4. The method of claim 1, wherein the patient has a baseline Epworth Sleepiness Scale (ESS) score greater than 10. 5. The method of claim 1, wherein the excessive sleepiness is excessive daytime sleepiness. 6. The method of claim 1, wherein the APC is provided as a pharmaceutically acceptable salt of APC. 7. The method of claim 6, wherein the APC is in the form of a hydrochloride salt. 8. The method of claim 1, wherein the patient has narcolepsy. 9. The method of claim 1, wherein the patient has obstructive sleep apnea. 10. A method of treating excessive sleepiness in a human patient with obstructive sleep apnea in need thereof, said method comprising administering [R]-2-amino-3-phenylpropylcarbamate (APC) or a pharmaceutically acceptable salt thereof to the human patient in accordance with a dosing regimen, said dosing regimen comprising a once-daily dose of 75 mg for at least 3 days followed by a once-daily dose of 150 mg, wherein the once-daily dose of 150 mg is the maximum dose in the dosing regimen, thereby treating excessive sleepiness in the human patient. 11. The method of claim 10, wherein the dosing regimen comprises a starting dose of 75 mg once daily for 3 days followed by a dose of 150 mg once daily. 12. The method of claim 10, wherein the dosing regimen comprises a starting dose of 37.5 mg once daily. 13. The method of claim 10, wherein the patient has a baseline ESS score greater than 10. 14. The method of claim 10, wherein the excessive sleepiness is excessive daytime sleepiness. 15. The method of claim 10, wherein the APC is provided as a pharmaceutically acceptable salt of APC. 16. The method of claim 15, wherein the APC is provided in the form of a hydrochloride salt. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
